Assignee
REMD BIOTHERAPEUTICS INC
US11 patents
Top patents by PatentIndex Score
US11319372B2May 3, 2022
Cancer treatment using antibodies that bind cytotoxic T-lymphocyte antigen-4 (CTLA-4)
REMD BIOTHERAPEUTICS INC3 citations72
US11629184B2Apr 18, 2023
Calcitonin gene-related peptide (CGRP) antagonist antibodies
REMD BIOTHERAPEUTICS INC0 citations62
US11446376B2Sep 20, 2022
Methods for treating heart failure using glucagon receptor antagonistic antibodies
REMD BIOTHERAPEUTICS INC0 citations62
US11332531B2May 17, 2022
Immunotherapy using antibodies that bind programmed death ligand-1 (PD-L1)
REMD BIOTHERAPEUTICS INC0 citations62
US11319376B2May 3, 2022
Combination of glucagon receptor antagonists and PI3K pathway inhibitors for the treatment of cancer
REMD BIOTHERAPEUTICS INC0 citations62
US11248049B2Feb 15, 2022
Immunotherapy using antibodies that bind Programmed Death 1 (PD-1)
REMD BIOTHERAPEUTICS INC0 citations62
US11447555B2Sep 20, 2022
Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
REMD BIOTHERAPEUTICS INC0 citations56
US11242398B2Feb 8, 2022
Anti-OX40 antibodies and methods of activating OX40
REMD BIOTHERAPEUTICS INC0 citations51
US10765737B2Sep 8, 2020
Methods for treating heart failure using glucagon receptor antagonistic antibodies
REMD BIOTHERAPEUTICS INC0 citations51
US10626179B2Apr 21, 2020
Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
REMD BIOTHERAPEUTICS INC0 citations45
US10752693B2Aug 25, 2020
Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
REMD BIOTHERAPEUTICS INC0 citations41